Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Approval    entities : Guardant health, inc.    save search
Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations
Published: 2023-09-05 (Crawled : 18:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.6M twitter stocktwits trandingview |
Health Services
 | | O: 0.0% H: 7.57% C: 0.86%
guardant360 lung japan diagnostic health her2 approval cancer cell treatment companion
Guardant Health announces reimbursement approval of Guardant360® CDx liquid biopsy test in Japan
Published: 2023-07-05 (Crawled : 13:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.6M twitter stocktwits trandingview |
Health Services
 | | O: -0.08% H: 3.58% C: 2.95%
guardant360 test japan health approval
Guardant Health Receives Regulatory Approval from Singapore's Health Sciences Authority for Guardant360® CDx blood test for patients with advanced solid cancers
Published: 2023-05-30 (Crawled : 01:00) - prnewswire.com
GH | News 4 | $18.1 4.38% 4.2% 1.6M twitter stocktwits trandingview |
Health Services
 | | O: 2.24% H: 3.41% C: -0.17%
guardant360 test health approval blood sciences
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test
Published: 2023-03-10 (Crawled : 17:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.6M twitter stocktwits trandingview |
Health Services
 | | O: -0.59% H: 0.3% C: -6.61%
blood drug test health application approval food
Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer
Published: 2023-01-30 (Crawled : 13:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.6M twitter stocktwits trandingview |
Health Services
 | | O: -1.0% H: 0.96% C: -0.93%
guardant360 treatment fda diagnostic breast health approval cancer esr1 mutation orserdu her2- her2 metastatic breast cancer
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Daiichi Sankyo and AstraZeneca’s ENHERTU® for Treatment of NSCLC Patients With Activating HER2 Mutations
Published: 2022-08-12 (Crawled : 13:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.6M twitter stocktwits trandingview |
Health Services
 | | O: 0.66% H: 2.77% C: 1.31%
guardant360 treatment fda diagnostic health approval her2- her2
Guardant Health Receives Regulatory Approval for Guardant360 CDx in Japan
Published: 2022-03-14 (Crawled : 10:00) - prnewswire.com
GH | News 4 | $18.1 4.38% 4.2% 1.6M twitter stocktwits trandingview |
Health Services
 | | O: -10.33% H: 0.0% C: 0.0%
health approval
FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer
Published: 2021-06-10 (Crawled : 10:52) - fda.gov
GH | News 4 | $18.1 4.38% 4.2% 1.6M twitter stocktwits trandingview |
Health Services
 | | O: -0.54% H: 7.61% C: 6.07%
cancer fda granted approval grant
Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen’s LUMAKRAS™ (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer
Published: 2021-05-28 (Crawled : 21:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.6M twitter stocktwits trandingview |
Health Services
 | | O: 0.82% H: 2.28% C: -0.95%
fda lung cancer fda approval cancer approval diagnostic
FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy
Published: 2021-05-28 (Crawled : 17:00) - prnewswire.com
GH | News 4 | $18.1 4.38% 4.2% 1.6M twitter stocktwits trandingview |
Health Services
 | | O: 0.82% H: 2.28% C: -0.95%
AMGN | News | $273.085 -0.17% -0.17% 2.5M twitter stocktwits trandingview |
Health Technology
 | | O: 0.38% H: 1.97% C: 0.73%
fda lung cancer therapy cancer drug fda approval approval
Guardant360® CDx Receives FDA Approval as Companion Diagnostic for Janssen’s RYBREVANT™ (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Published: 2021-05-21 (Crawled : 23:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.6M twitter stocktwits trandingview |
Health Services
 | | O: 0.53% H: 2.94% C: 0.73%
fda lung cancer fda approval cancer approval diagnostic
FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer
Published: 2021-05-21 (Crawled : 18:33) - fda.gov
GH | News 4 | $18.1 4.38% 4.2% 1.6M twitter stocktwits trandingview |
Health Services
 | Email alert Add to watchlist
fda cancer approval granted grant
Gainers vs Losers
62% 38%

Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M twitter stocktwits trandingview |
Consumer Services
BOF | $1.99 70.09% 41.21% 110M twitter stocktwits trandingview |

ILAG | $0.51 6.03% 40.62% 1.7M twitter stocktwits trandingview |

LICN | $0.941 68.04% 40.49% 15M twitter stocktwits trandingview |

AMST | $3.31 65.5% 39.58% 70M twitter stocktwits trandingview |
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M twitter stocktwits trandingview |
Technology Services
WIMI | $1.15 58.53% 36.92% 19M twitter stocktwits trandingview |
Technology Services
AIH | $0.45 12.5% 30.92% 320K twitter stocktwits trandingview |
Health Services
MULN | News | $3.78 38.46% 27.78% 13M twitter stocktwits trandingview |
Information
RILY | $29.86 37.48% 27.26% 12M twitter stocktwits trandingview |
Finance
Your saved searches
Save your searches and get alerts when important news are released.